Ovid Therapeutics (NASDAQ:OVID) has been assigned a $20.00 target price by investment analysts at Piper Jaffray Companies in a research note issued on Monday. The firm currently has a “buy” rating on the stock. Piper Jaffray Companies’ target price would suggest a potential upside of 224.68% from the stock’s previous close. Piper Jaffray Companies also issued estimates for Ovid Therapeutics’ Q2 2018 earnings at ($0.55) EPS, Q3 2018 earnings at ($0.55) EPS, Q4 2018 earnings at ($0.56) EPS, FY2018 earnings at ($2.20) EPS, Q1 2019 earnings at ($0.55) EPS, Q2 2019 earnings at ($0.60) EPS, Q3 2019 earnings at ($0.60) EPS, Q4 2019 earnings at ($0.65) EPS, FY2019 earnings at ($2.40) EPS, FY2020 earnings at ($3.10) EPS, FY2021 earnings at ($3.60) EPS and FY2022 earnings at ($2.25) EPS.

OVID has been the subject of several other reports. LADENBURG THALM/SH SH assumed coverage on shares of Ovid Therapeutics in a report on Friday, April 20th. They issued a “buy” rating and a $27.00 price objective for the company. BidaskClub upgraded shares of Ovid Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, July 15th. Zacks Investment Research upgraded shares of Ovid Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, April 12th. Finally, ValuEngine upgraded shares of Ovid Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Ovid Therapeutics presently has an average rating of “Hold” and an average price target of $19.33.

NASDAQ OVID traded up $0.14 during trading on Monday, hitting $6.16. The company had a trading volume of 83,647 shares, compared to its average volume of 102,543. Ovid Therapeutics has a one year low of $5.41 and a one year high of $12.44. The firm has a market capitalization of $148.23 million, a PE ratio of -1.84 and a beta of 2.05.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.53) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.07. research analysts expect that Ovid Therapeutics will post -2.51 EPS for the current year.

Several institutional investors have recently modified their holdings of the stock. DRW Securities LLC bought a new stake in Ovid Therapeutics during the 1st quarter valued at about $108,000. California State Teachers Retirement System increased its stake in Ovid Therapeutics by 109.8% during the 1st quarter. California State Teachers Retirement System now owns 18,676 shares of the company’s stock valued at $132,000 after purchasing an additional 9,776 shares in the last quarter. Spark Investment Management LLC increased its stake in Ovid Therapeutics by 83.3% during the 1st quarter. Spark Investment Management LLC now owns 19,800 shares of the company’s stock valued at $139,000 after purchasing an additional 9,000 shares in the last quarter. Acadian Asset Management LLC increased its stake in Ovid Therapeutics by 165.4% during the 2nd quarter. Acadian Asset Management LLC now owns 19,729 shares of the company’s stock valued at $154,000 after purchasing an additional 12,294 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Ovid Therapeutics by 482.8% during the 1st quarter. JPMorgan Chase & Co. now owns 33,006 shares of the company’s stock valued at $233,000 after purchasing an additional 27,343 shares in the last quarter. Institutional investors own 28.55% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.

Recommended Story: What does RSI mean?

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.